Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

About one in eight adults say they are taking a GLP-1 receptor agonist as a treatment for obesity, diabetes or another ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for ...

A select few hits have led the chart for at least 10 weeks. By Gary Trust Beginning with Debby Boone’s “You Light Up My Life” in 1977, a relatively select few smashes have led the Billboard Hot 100 ...

It's safe to say that Xiaomi is the most talked-about new brand on the Indian tech scene today. The Chinese company has not spent any money on advertising and in fact seems pretty laid back about all ...